Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D).[6][7] It is administered via intraveneous infusion.[5] It was approved for medical use in the European Union and in the United States in 2015.[8][6][5][7]
^"Sebelipase alfa (Kanuma) Use During Pregnancy". Drugs.com. 14 June 2019. Retrieved 4 May 2020.
^"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^"Genetic disorders". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^ abc"Kanuma- sebelipase alfa injection, solution, concentrate". DailyMed. 18 December 2018. Retrieved 4 May 2020.
Sebelipasealfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the...
asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipasealfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa)...
Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation...
Asfotase alfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia...
disease/CESD) Sebelipasealfa IV MPS I Laronidase IV MPS II Idursulfase IV MPS IVA Elosulfase alfa IV MPS VI Galsulfase IV Pompe disease Alglucosidase alfa (160L...
beyond the first year of life. In 2015, an enzyme replacement therapy, sebelipasealfa, was approved in the US and EU. The therapy was additionally approved...
Global Information